An overview of new GLP-1 receptor agonists for type 2 diabetes

被引:50
作者
Tomlinson, Brian [1 ,2 ,3 ]
Hu, Miao [2 ]
Zhang, Yuzhen [1 ]
Chan, Paul [3 ]
Liu, Zhong-Min [4 ]
机构
[1] Tongji Univ, Sch Med, Shanghai East Hosp, Res Ctr Translat Med, Shanghai 200120, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
[3] Taipei Med Univ, Wan Fang Hosp, Div Cardiol, Dept Internal Med, 111,Sec 3,Hsin Lung Rd, Taipei 116, Taiwan
[4] Tongji Univ, Shanghai East Hosp, Dept Cardiac Surg, 150 Jimo Rd, Shanghai 200120, Peoples R China
关键词
Efpeglenatide; GLP-1; GLP-1 receptor agonist; glymera; semaglutide; type 2 diabetes mellitus; GLUCAGON-LIKE PEPTIDE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; CONTINUOUS SUBCUTANEOUS DELIVERY; TWICE-DAILY EXENATIDE; CARDIOVASCULAR OUTCOMES; GLUCOSE-TOLERANCE; BLOOD-PRESSURE; ORAL GLUCOSE; HEART-RATE; POSTPRANDIAL LIPEMIA;
D O I
10.1517/13543784.2016.1123249
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Introduction: The increasing prevalence of type 2 diabetes mellitus (T2DM) and the eventual need for multiple medications in most patients stimulated the development of new drug classes to reduce plasma glucose levels. The GLP-1 receptor agonists (GLP-1RAs) are established as an option for treatment of T2DM after metformin. They are also effective in reducing body weight but current GLP-1RAs have to be given by subcutaneous injection daily or once weekly.Areas covered: This review focuses on the new GLP-1RAs currently undergoing development, some of which require less frequent subcutaneous administration and others that are being developed in oral formulations that may favor patient adherence.Expert opinion: The new GLP-1RAs may have the benefit of requiring less frequent subcutaneous dosing or being active by oral administration. However, cardiovascular outcome trials have shown that DPP4 inhibitors are neutral for cardiovascular events and the first cardiovascular outcome trial with lixisenatide reported similar results, whereas the trial with the SGLT2 inhibitor empagliflozin showed a reduction in cardiovascular events. These findings in patients with high cardiovascular risk may favor the use of SGLT2 inhibitors as a second line treatment after metformin but there should still be an important role for novel GLP-1RAs, especially when weight reduction is required.
引用
收藏
页码:145 / 158
页数:14
相关论文
共 108 条
[1]
[Anonymous], 2015, DIAB SUMM 2015 APR 2
[2]
[Anonymous], 2014, IDF Diabetes Atlas, V6th
[3]
[Anonymous], 2015, AM DIAB ASS ADA 75 S
[4]
[Anonymous], 2014, AM DIAB ASS ADA 74 S
[5]
[Anonymous], 2010, AM DIAB ASS ADA 70 S
[6]
Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes [J].
Bagger, Jonatan I. ;
Knop, Filip K. ;
Lund, Asger ;
Vestergaard, Henrik ;
Holst, Jens J. ;
Vilsboll, Tina .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (03) :737-745
[7]
An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose Homeostasis [J].
Baggio, Laurie L. ;
Huang, Qingling ;
Cao, Xiemin ;
Drucker, Daniel J. .
GASTROENTEROLOGY, 2008, 134 (04) :1137-1147
[8]
Biology of incretins: GLP-1 and GIP [J].
Baggio, Laurie L. ;
Drucker, Daniel J. .
GASTROENTEROLOGY, 2007, 132 (06) :2131-2157
[9]
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight [J].
Baggio, Laurie L. ;
Drucker, Daniel J. .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (10) :4223-4226
[10]
Safety of antidiabetes medications: An update [J].
Bailey, C. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (02) :185-195